Aspirin for Heart Disease Prevention in Women: A Different Risk-Benefit Calculation

The aspirin primary prevention story in women is distinctly different from men’s. Where the Physicians’ Health Study showed aspirin reduced MI in men without reducing stroke, the Women’s Health Study showed aspirin reduced stroke in women without reducing MI. This sex-differentiated response is not coincidental, it reflects differences in platelet biology, clotting factor expression, and the underlying mechanisms of arterial thrombosis between sexes. Understanding this distinction is essential for interpreting what the current guidance means for individual women.

For women, the aspirin conversation also touches areas that simply do not arise in men’s cardiovascular medicine: preeclampsia prevention in pregnancy, antiphospholipid syndrome, and the cardiovascular consequences of early menopause. These create a more complex landscape where aspirin’s indications overlap and diverge in ways that a single guideline cannot fully capture. A woman asking her cardiologist about aspirin may be asking about three completely different things without realizing it.

The Women’s Health Study: The Foundational Evidence

The Women’s Health Study (WHS) is the primary source of sex-specific evidence on aspirin for cardiovascular prevention in women. It enrolled 39,876 apparently healthy women aged 45 and older, who were randomized to aspirin 100mg every other day versus placebo, with a median follow-up of approximately 10 years. Results were published in the New England Journal of Medicine in 2005. 5 / Solid

The primary composite endpoint, major adverse cardiovascular events including nonfatal MI, nonfatal stroke, and cardiovascular death, showed no statistically significant reduction in the aspirin group across the full study population. This non-significant result created the initial impression that aspirin simply did not work in women. That reading was incomplete.

When the data were examined in detail, a sex-differentiated pattern emerged that mirrored the male pattern from PHS in an inverted form. The aspirin group showed a 17% reduction in all stroke, driven primarily by reductions in ischemic stroke. There was no reduction in myocardial infarction in the aspirin group for women overall. This is the opposite of what PHS found in men, where MI was reduced but stroke was not. The consistency of this sex-divergent pattern across both large trials strongly suggests that the difference is biologically meaningful rather than statistical noise.

The age-stratified analysis added further complexity. In women aged 65 and older, aspirin produced statistically significant reductions in both myocardial infarction (approximately 34% reduction) and stroke (approximately 30% reduction). The cardiovascular benefit of aspirin in women appeared to manifest most clearly in older women. Younger women in the WHS showed a stroke benefit but not an MI benefit, while older women showed both. This age-dependent benefit pattern has important implications for how aspirin decisions are made across a woman’s cardiovascular life course.

As in all aspirin trials, the benefit in WHS came with a bleeding cost. Major gastrointestinal bleeding was significantly higher in the aspirin group, and there was a numerical trend toward increased hemorrhagic stroke, consistent with aspirin’s mechanism of action.

Why Women’s Platelet Biology Differs

The divergent outcomes in WHS and PHS are mechanistically intriguing. Several biological differences between men and women are relevant, though the complete picture involves considerable scientific uncertainty.

Women have higher mean platelet volume on average and show different patterns of platelet turnover across the life cycle. Platelet reactivity in women is influenced by hormonal status: estrogen modulates thromboxane A2 synthesis, prostaglandin I2 (prostacyclin) production, and platelet receptor expression. These effects are complex, partly because estrogen influences both pro- and anti-thrombotic pathways simultaneously. Following menopause, the loss of estrogen’s modulatory effects shifts the platelet environment, which may partly explain why older women in WHS showed greater aspirin benefit than younger women.

Women also have, on average, higher levels of von Willebrand factor (vWF) and factor VIII than men of comparable age. Von Willebrand factor mediates platelet adhesion to damaged vascular endothelium and is a key determinant of primary hemostasis. Higher vWF levels may make women’s platelets more adhesive in certain vascular injury contexts, particularly in conditions like atrial fibrillation or cerebrovascular disease, where platelet-vWF interactions play an important role in thrombus formation.

The coagulation factor differences between sexes also interact with the epidemiology of cardiovascular events. Women’s cardiovascular events are more likely than men’s to involve embolic stroke and microvascular disease, while men’s are more often classic plaque-rupture MI. If aspirin’s antiplatelet effect is more relevant to the platelet-thrombotic component of stroke than to the plaque-rupture component of MI, this could explain why women benefit more in the stroke domain and men benefit more in the MI domain.

These are mechanistic hypotheses that are consistent with the observed data but not yet definitively proven. The important clinical point is that the divergent WHS and PHS outcomes are real, substantial across large populations, and should inform sex-specific discussions about aspirin.

Stroke Risk in Women and Aspirin’s Relevance

Cardiovascular disease is frequently discussed as a male condition, but stroke is the second leading cause of death in women and causes more deaths in women than in men in absolute numbers. Women’s lifetime stroke risk exceeds their lifetime MI risk in many populations, whereas in men the relationship is reversed. This difference in event-type distribution makes the stroke-specific benefit of aspirin more relevant to women’s cardiovascular health than is sometimes recognized.

Risk factors for stroke with particular female relevance include atrial fibrillation, hypertension, migraine with aura, antiphospholipid syndrome, prior preeclampsia, and early menopause. Some of these risk factors are more prevalent in women or carry stronger stroke risk associations in women than in men. Migraine with aura, for instance, is a much stronger stroke risk factor in women than in men, and the presence of aura significantly elevates ischemic stroke risk.

Aspirin’s demonstrated 17% stroke reduction across the full WHS population, and larger reductions in women over 65, is clinically meaningful in the context of women’s overall stroke burden. However, the concurrent risk of hemorrhagic stroke on aspirin, and the significant GI bleeding risk, must be weighed against this benefit. The net calculation requires the same individualized approach that the guidelines recommend: estimating absolute cardiovascular event risk, assessing bleeding risk factors, and making a shared decision.

Atrial fibrillation, a major cause of cardioembolic stroke in women, is not an indication for aspirin. Women with AF require anticoagulation with either warfarin or a direct oral anticoagulant for stroke prevention; aspirin is substantially less effective for AF-related stroke and is not guideline-recommended for this purpose. A general aspirin recommendation does not constitute adequate stroke prevention if AF is present.

The Modern Trials and Updated Calculus

The three large 2018 trials that reshaped aspirin guidance enrolled women as well as men, and their findings broadly apply to women.

ASPREE enrolled women aged 70 and older (and 65 and older for underrepresented groups) without cardiovascular disease or disability. In this older female population, aspirin 100mg per day produced no improvement in disability-free survival and caused significantly increased major hemorrhage. 5 / Solid The ASPREE findings are consistent with the WHS age-stratified data in one important respect: even if older women show some cardiovascular benefit from aspirin, the hemorrhagic cost in this age group is large enough to eliminate the net benefit in a healthy population without established disease.

ARRIVE enrolled moderate-risk men and women and found no significant reduction in cardiovascular events with aspirin, paired with doubled major GI bleeding. 5 / Solid Notably, the study population’s event rate was lower than predicted, which reduced statistical power, but this is itself an important finding that moderate-risk women may not reach the event rates that make aspirin primary prevention cost-effective.

ASCEND enrolled women with type 2 diabetes without established cardiovascular disease. As in men, the 12% relative vascular event reduction in the aspirin group was offset by an equivalent absolute increase in major bleeding, yielding approximately zero net benefit across the overall population. 5 / Solid Women with diabetes had been a population where aspirin was often recommended based on their elevated cardiovascular risk; ASCEND substantially changed that default.

The 2022 USPSTF recommendations reflect the totality of this evidence. The recommendations apply without sex differentiation: against initiating aspirin for primary prevention in adults 60 and older; individualized shared decision-making for adults 40 to 59 with 10-year cardiovascular disease risk of 10% or greater.

Aspirin in Pregnancy: A Completely Different Indication

Aspirin’s role in pregnancy-related preeclampsia prevention is entirely distinct from its role in cardiovascular primary prevention and deserves separate treatment to avoid confusion.

Low-dose aspirin, typically 81mg per day initiated after 12 weeks of gestation, is strongly recommended by the USPSTF for prevention of preeclampsia in women at high risk for the condition. 5 / Solid The USPSTF assigns this a Grade B recommendation, meaning it should be offered to all eligible high-risk women.

High-risk criteria for preeclampsia prevention with aspirin include: prior preeclampsia (the single strongest risk factor), multifetal gestation, chronic hypertension, type 1 or type 2 diabetes, kidney disease, and autoimmune conditions including systemic lupus erythematosus and antiphospholipid syndrome. Women with multiple moderate-risk factors (first pregnancy, obesity, age over 35, Black race, family history of preeclampsia, low socioeconomic status) may also qualify for aspirin recommendation depending on the constellation of risk.

The mechanism in this context is completely different from atherosclerotic event prevention. Preeclampsia involves abnormal placental vascularization and placental ischemia, with downstream maternal endothelial dysfunction and hypertension. Aspirin’s anti-thromboxane effect reduces the placental vascular resistance and platelet-mediated endothelial injury that contribute to this process.

Critically, women who took aspirin during pregnancy for preeclampsia prevention should not assume they have any ongoing indication for aspirin for long-term cardiovascular primary prevention. The preeclampsia indication is time-limited to pregnancy. It does not extend to post-partum cardiovascular prevention. However, a history of preeclampsia is itself an important cardiovascular risk marker: women with prior preeclampsia have a two- to fourfold increased lifetime risk of cardiovascular disease, and this history should be disclosed to their cardiologist as it informs future risk assessment and potentially the threshold for cardiovascular primary prevention interventions.

Antiphospholipid Syndrome: A Women-Specific Indication

Antiphospholipid syndrome is a prothrombotic autoimmune condition in which antibodies against phospholipid-binding proteins (anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, lupus anticoagulant) cause an acquired hypercoagulable state. The condition has a strong female predominance of approximately 3 to 1, and it frequently occurs in younger women, sometimes in association with systemic lupus erythematosus.

The cardiovascular and thrombotic presentations of APS are wide-ranging: venous thromboembolism (DVT, pulmonary embolism), arterial thrombosis (ischemic stroke, MI, peripheral arterial occlusion), pregnancy loss, and preeclampsia. The treatment approach depends on the thrombotic history. Women with APS and a history of arterial thrombosis, including ischemic stroke or MI, have strong indications for anticoagulation; some protocols also incorporate aspirin. Women with APS and obstetric complications (pregnancy loss, preeclampsia) without prior thrombosis are commonly treated with aspirin plus prophylactic anticoagulation during pregnancy.

APS represents a meaningful reason a woman may be appropriately maintained on aspirin that has nothing to do with standard atherosclerotic cardiovascular risk prevention. Women who have been told they have APS and are taking aspirin for that reason should not discontinue it based solely on USPSTF primary prevention guidance, which is not intended to apply to this autoimmune thrombotic condition.

Cardiovascular Risk Assessment in Women: Important Gaps

Standard cardiovascular risk calculators, including the Pooled Cohort Equations widely used to estimate 10-year ASCVD risk, were developed using cohorts that have known representation gaps for women. The calculators tend to underestimate risk in women with certain high-risk conditions that are not captured in the equation inputs.

Prior preeclampsia is the most important example. Women with a history of preeclampsia have significantly elevated long-term cardiovascular risk that is not reflected in their standard Pooled Cohort Equations score. A woman aged 45 with a prior preeclampsia history and otherwise moderate traditional risk factors may have a true 10-year risk considerably higher than her calculated score suggests.

Autoimmune conditions also elevate cardiovascular risk beyond what calculators capture. Women with systemic lupus erythematosus, rheumatoid arthritis, or antiphospholipid syndrome have higher cardiovascular event rates than age-matched women without these conditions. Guidelines from several cardiology societies now recommend treating these conditions as cardiovascular risk enhancers when making treatment decisions.

Early menopause, defined as occurring before age 45, is associated with elevated cardiovascular risk through mechanisms including earlier loss of estrogen’s vascular protective effects and possible shared pathophysiology with vascular disease. This risk elevation is also not captured in standard Pooled Cohort Equations inputs.

These gaps matter because they affect the primary prevention decision. A woman who appears to be below the 10% 10-year risk threshold based on her Pooled Cohort Equations calculation may actually be above it when risk enhancers are considered. Some cardiologists incorporate coronary artery calcium scoring in this calculation as a way to refine risk estimates for women who appear to be near the treatment threshold and have risk enhancers.

Who Among Women Retains a Strong Indication

Secondary prevention (established coronary artery disease, prior MI, prior ischemic stroke or TIA attributable to atherosclerosis, symptomatic peripheral artery disease) remains a Class I indication for aspirin 75 to 100mg per day. The secondary prevention evidence base in women is consistent and strong. Women with established cardiovascular disease should be on aspirin regardless of the shifts in primary prevention guidance.

High-risk primary prevention women aged 40 to 59 with a 10-year cardiovascular disease risk of 10% or greater may engage in individualized shared decision-making. Women in this category who also have prior preeclampsia, autoimmune disease, or other risk enhancers that elevate their true risk above the calculator estimate may have a stronger case for consideration.

Preeclampsia prevention in high-risk pregnancy is a distinct, well-supported indication that should not be confused with general cardiovascular primary prevention.

Women with antiphospholipid syndrome should have their aspirin use managed in the context of their overall anticoagulation and thrombosis management plan, which is distinct from standard cardiovascular primary prevention guidelines.

Synthesis

The aspirin story in women illustrates that sex matters in clinical trial design, data analysis, and guideline development. The WHS established that aspirin’s cardiovascular effects in women are not simply a scaled version of its effects in men. Women’s dominant benefit is in stroke reduction; men’s is in MI reduction. Older women show broader cardiovascular benefit than younger women. These patterns are biologically plausible and clinically reproducible across subsequent trials.

The convergence of the 2018 trials with the WHS long-term data supports the same general conclusion for women as for men: primary prevention aspirin does not produce a net benefit large enough to recommend routinely in most women without established cardiovascular disease. The benefit is real but modest, the bleeding risk is real and scales with age, and the net equation does not favor aspirin as a general recommendation.

The distinctly women-centered indications, preeclampsia prevention in pregnancy and aspirin’s role in antiphospholipid syndrome management, are not affected by primary prevention guidance and remain strong evidence-based uses. Women with established cardiovascular disease retain aspirin as a cornerstone of secondary prevention.

For women without established disease, the primary prevention conversation is appropriately individualized. A woman’s sex-specific cardiovascular history, including pregnancy complications and autoimmune disease, should be part of that individualized assessment in a way that standard cardiovascular risk algorithms do not automatically incorporate.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.